文献速递临床免疫临床生化分子诊断

胰腺炎生物标志物免疫检测技术进展

Advances in Immunoassays for detection of pancreatitis biomarkers.
PubMed 文献 · Clin Chim Acta · 2025-07-17

本文综述了用于胰腺炎生物标志物定量的免疫分析技术进展,包括高敏脂肪酶和淀粉酶ELISA、化学发光和时间分辨荧光、无标记等离子体传感器、数字单分子平台及多重珠基和微阵列系统。文章汇总了经典酶学标志物、已确立蛋白及新兴分子靶标的分析性能指标,并讨论了检测标准化、头对头验证和预分析变异等挑战。

要点

  • 高敏免疫分析技术可提升胰腺炎生物标志物检测的敏感性和通量。
  • 脂肪酶和淀粉酶是胰腺炎经典酶学标志物,CRP和TAP为已确立蛋白标志物。
  • 检测标准化和预分析变异是当前胰腺炎免疫分析面临的主要挑战。

核心结论

  • 先进免疫分析技术与胰腺炎特异性生物标志物性能的整合,将技术创新与临床适用性相联系。

研究设计与样本

  • 本文为综述,检索范围未在摘要中明确报告。

主要发现

  • 综述涵盖高敏脂肪酶和淀粉酶ELISA、化学发光和时间分辨荧光、无标记等离子体传感器、数字单分子平台及多重珠基和微阵列系统。
  • 综述汇总了经典酶学标志物(脂肪酶、淀粉酶)、已确立蛋白(CRP、TAP)及新兴分子靶标(细胞因子、DAMPs、microRNAs)的数据。
  • 分析性能评估聚焦于敏感性、特异性、动态范围、精密度和稳健性,并涉及预分析因素和临床应用。

关键数值与推荐

  • 当前挑战包括检测标准化、头对头验证和预分析变异。
  • 微流控「芯片实验室」和即时检测平台的应用潜力被探讨。

临床怎么用

  • 先进免疫分析可用于胰腺炎早期诊断、严重程度评估和治疗反应评价。

局限性

  • 摘要未明确报告本综述的检索范围及纳入文献的样本量等局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pancreatitis is a predominant cause of gastrointestinal morbidity. However, the early and accurate detection of biomarkers, which is essential for guiding risk stratification and therapeutic decision-making, is constrained by the sensitivity and throughput limitations of conventional assays. This review critically examines advances in immunoassay technologies, including high-sensitivity lipase and amylase ELISAs, chemiluminescence and time-resolved fluorescence formats, label-free plasmonic sensors, digital single-molecule platforms, and multiplex bead-based and microarray systems, as applied to pancreatitis biomarker quantitation. This study synthesizes data on classical enzymatic markers, such as lipase and amylase, established proteins, including C-reactive protein and trypsinogen activation peptide, and emerging molecular targets, such as cytokines, DAMPs, and microRNAs. The focus is on evaluating analytical performance metrics, including sensitivity, specificity, dynamic range, precision, and robustness, along with preanalytical factors and clinical applications. These components are analyzed in relation to early diagnosis, assessment of severity, and evaluation of therapeutic response. Current challenges in assay standardization, head-to-head validation, and preanalytical variability are highlighted, and the potential of microfluidic "lab-on-a-chip" and point-of-care platforms is explored. This review effectively integrates advanced immunoassay modalities with the performance of pancreatitis-specific biomarkers, thereby uniquely linking technological innovation to clinical applicability. This study aims to offer a prioritized roadmap for the development and implementation of standardized multiplexed assays in personalized pancreatitis diagnostics.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Srinivasamurthy SK, Mittal P, Saleem S, et al. Advances in Immunoassays for detection of pancreatitis biomarkers. Clin Chim Acta. 2025. PMID: 40683403. doi:10.1016/j.cca.2025.120492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。